Loading...
XNYSARMP
Market cap72mUSD
Jan 15, Last price  
2.00USD
1D
-0.58%
1Q
-15.13%
Jan 2017
-96.75%
Name

Armata Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNYS:ARMP chart
P/E
—
P/S
15.99
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
92.59%
Rev. gr., 5y
-36.56%
Revenues
5m
-17.77%
18,880,00019,333,00014,073,0009,652,0006,874,0009,864,00010,332,0008,718,000664,000325,000409,000475,000260,000115,00000823,0004,474,0005,508,0004,529,000
Net income
-69m
L+87.17%
-27,170,000-23,767,000-14,833,000-14,257,000-19,198,000-33,990,000-16,127,000-20,720,000-1,110,000-58,411,00023,109,000-516,000-18,838,000-12,838,000-12,110,000-19,025,000-22,815,000-23,219,000-36,888,000-69,045,000
CFO
-47m
L+46.00%
-23,543,000-20,096,000-11,230,000-15,523,000-16,391,000-11,636,000-13,882,000-10,305,000-4,281,000-7,448,000-12,572,000-9,781,000-10,589,000-9,192,000-9,382,000-15,582,000-18,270,000-23,575,000-32,481,000-47,423,000
Earnings
Mar 19, 2025

Profile

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
URL
https://www.armatapharma.com/
IPO date
May 20, 1994
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,529
-17.77%
5,508
23.11%
Cost of revenue
79,189
43,346
Unusual Expense (Income)
NOPBT
(74,660)
(37,838)
NOPBT Margin
Operating Taxes
(29)
Tax Rate
NOPAT
(74,660)
(37,809)
Net income
(69,045)
87.17%
(36,888)
58.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
44,391
BB yield
-104.39%
Debt
Debt current
18,962
17,011
Long-term debt
148,954
80,619
Deferred revenue
(31,804)
Other long-term liabilities
31,804
Net debt
154,393
76,818
Cash flow
Cash from operating activities
(47,423)
(32,481)
CAPEX
(8,144)
(2,211)
Cash from investing activities
(8,134)
(2,211)
Cash from financing activities
53,988
44,016
FCF
(94,457)
(49,320)
Balance
Cash
13,523
14,852
Long term investments
5,960
Excess cash
13,297
20,537
Stockholders' equity
(308,458)
(239,413)
Invested Capital
411,622
324,308
ROIC
ROCE
EV
Common stock shares outstanding
36,076
34,294
Price
3.24
161.29%
1.24
-77.37%
Market cap
116,885
174.86%
42,525
-67.81%
EV
271,278
119,343
EBITDA
(73,688)
(36,946)
EV/EBITDA
Interest
2,626
29
Interest/NOPBT